BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) investors concerning the Company’s possible violations of federal securities laws.
On September 11, 2023, after the markets closed, Acelyrin announced top-line results from Part B of a Phase 2b/3 trial of its Hidradenitis Suppurativa (HS) treatment, izokibep. The Company disclosed that the “primary endpoint of HiSCR75 at week 16 did not meet statistical significance” and that “[in] the primary NRI analysis of Part B, statistical significance was impacted by patients with HiSCR75-100 discontinuing as early as week 4 unrelated to adverse events.”
On this news, Acelyrin's stock price fell $17.19, or 61.6%, over the next two consecutive trading days, to close at $10.71 per share on September 13, 2023, thereby injuring investors.
If you purchased Acelyrin securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.